Cochrane Abstracts
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide New
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide New is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Prognostic Value of Test(s) for O6‐methylguanine–DNA Methyltransferase (MGMT) Promoter Methylation for Predicting Overall Survival in People With Glioblastoma Treated With Temozolomide New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6���methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide_New. Accessed 02 February 2023.
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6���methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide_New. Accessed February 2, 2023.
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide New. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6���methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide_New
Prognostic Value of Test(s) for O6‐methylguanine–DNA Methyltransferase (MGMT) Promoter Methylation for Predicting Overall Survival in People With Glioblastoma Treated With Temozolomide New [Internet]. In: Cochrane Abstracts. [cited 2023 February 02]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6���methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide New
ID - 431926
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6���methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide_New
DB - Evidence Central
DP - Unbound Medicine
ER -
